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Synopsis: 
Surgical resection is the only potential curative treatment of intra-hepatic cholangiocarcinoma 
(ICC). However, few patients are resectable and curently no treatments have proved efficacy 
for the downstagging. We report our experience of 8 initially unresectable ICC, downstaged 
by Yttrium-90 radioembolization plus systemic chemotherapy, and secondarily operated. 
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Abstract 
Purpose: To evaluate the downstaging efficacy of yttrium-90 radioembolization (Ytt-90)-
associated with chemotherapy and the results of surgery for initially unresectable huge ICC.  
Methods: Between January 2008 and October 2013, unresectable ICC were treated with 
chemotherapy and Ytt-90. Patients with unique tumors localized to non-cirrhotic livers and 
without extra-hepatic metastasis were considered as potentially resectable and were evaluated 
every 2 months for possible secondary resection. 
Results:  Forty-five patients were treated for unresectable ICCs; 10 had potentially resectable 
tumors, and 8 underwent surgery. Initial unresectability was due to the involvement of the 
hepatic veins or portal vein of the future liver remnant in 7 and 1 cases, respectively. Pre-
operative treatment induced significant decreases in tumor volume (295 versus 168 ml, 
p=0.02) and allowed for R0 resection in all cases. Three (37.5%) patients had Clavien-Dindo 
grade ≥ 3 complications, including two postoperative deaths. The median follow-ups were 
15.6 [4 – 40.7] months after medical treatment initiation and 7.2 [0.13 - 36.4] months post-
surgery. At the end of the study period, five patients were still alive with one patient still alive 
40 months after medical treatment initiation (36.4 months post-surgery), two patients 
experienced recurrences. 
Conclusions: For initially unresectable huge ICCs, chemotherapy with Ytt-90 
radioembolization is an effective downstaging method that allows for secondary resectability. 
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INTRODUCTION: 
 
Although rare, intrahepatic cholangiocarcinomas (ICC) are the second most frequent primary 
liver cancer after hepatocellular carcinomas (HCC). 1, 2 ICC account for 5 to 10% of primary 
liver malignancies,1 and their incidence has significantly increased over the last two decades 3-
5. 
Complete surgical resection remains the only potentially curative treatment 6, 7. However, 
because these tumors remain clinically silent, patients are generally diagnosed when the 
tumors are huge. Resection is therefore frequently impossible or incomplete,7 and recurrence 
rates remain high.8-10 
For patients with huge ICC, non-resectability results from the vascular involvement (i.e., 
glissonian vessels and hepatic veins) of the potential future liver remnant (FLR).  In these 
patients, tumor downsizing can improve the resectability and eventually lead to curative 
treatment, regardless of the method used to achieve downsizing. Currently, no preoperative 
treatment has proven to be efficient in this setting. 
Radioembolization using yttrium-90 (Ytt-90) has demonstrated its efficacy in the palliative 
treatment of HCC 11, 12 and ICC.13-16 Our team has previously reported that, in HCC patients, 
Ytt-90 radioembolization is effective in reducing tumor volumes and simultaneously inducing 
hypertrophy of the liver contralateral to the tumor. 17 This combined effect might allow for 
secondary resection in patients who are initially unresectable. 
The aim of this study was to report our experience with initially unresectable patients with 
huge ICC who were first treated with a combination of intra-arterial Ytt-90 radioembolization 
and systemic chemotherapy and subsequently became secondarily resectable. 
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PATIENTS AND METHODS 
Patients 
Between January 2008 and October 2013, all patients with mass-forming type ICC that were 
judged to be unresectable by a multidisciplinary committee including oncologists, radiologists 
and senior surgeons were offered a combination of intra-arterial Ytt-90 radioembolization and 
systemic chemotherapy as a palliative treatment. The inclusion criteria were a biopsy-proven 
ICC, an Eastern Cooperation Oncology Group (ECOG) performance status ≤ 2,18 and 
adequate liver function (i.e., a normal bilirubin blood level). The treated patients were closely 
monitored with physical examinations, biology tests, evaluations of the side effects after each 
chemotherapy cycle, and CT-scans every 2 months. 
This retrospective study received approval from the local ethical committee (authorization 
number 14.28). 
 
Chemotherapy and Ytt-90 radioembolization  
Systemic chemotherapy was first initiated using gemcitabine and/or platinum salts. 
Gemcitabine was not administered in the cycles before and after each radioembolization to 
avoid possible increases in toxicity. 
The Ytt-90 radioembolizations were administered few weeks after the initiation of the 
chemotherapy as previously described.17 Briefly, a supra-selective diagnostic angiography 
with Tc-99m macro-aggregated albumin was first performed to evaluate pulmonary shunting 
and the absence of digestive uptake and to calculate the Ytt-90 activity according to target 
volume. Therapeutic arteriography was performed 8 days later using glass microspheres 
(Therasphere®). When necessary, a second injection was administered 1 month later to treat 
the entire tumor.  Chemotherapy was pursued after radioembolization. 
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Tumor response and resectability criteria: 
All patients underwent CT-scan prior to the initiation of chemotherapy and every 2 months 
thereafter with evaluation of the tumor responses by the multidisciplinary committee. Patients 
with solitary tumors on non-cirrhotic livers and an absence of extra-hepatic metastases were 
considered for potential resection. Resectability was defined as the possible complete removal 
of the tumor regardless of the margin width and regardless of the technique (i.e., in situ or ex 
vivo resections) and with the use of complex vascular reconstruction when necessary.  When 
tumor resectability was possible in terms of the anatomical criteria, but the future liver 
remnant volume (FLRV) represented less than 30% of the total liver volume (TLV), 
additional portal vein embolization was performed. The liver resections included hilar 
lymphadenectomy in all cases. The extrahepatic bile duct was resected when necessary, and 
bilioenteric anastomosis using a Roux-en-Y was performed. The time between the last 
chemotherapy cycle and the surgery was at least one month.  
 
Survival analyses 
The overall survivals (OS) were calculated from the time of the initiation of chemotherapy 
and from the time of surgery. 
Disease-free survivals (DFS) were calculated from time of surgery. 
 
Statistical analyses 
The quantitative variables are expressed as the medians with ranges. Categorical variables are 
expressed as numbers and percentages. Volumetric values were compared with paired 
Wilcoxon tests. 
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Survival analyses were performed using the Kaplan-Meier method. Statistical analyses were 
performed with the R statistical software version 3.0.0.  Volumetric analyses were performed 
using the Myrian® Xp liver software. Differences were considered significant when p<0.05. 
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RESULTS 
 
During the study period, 45 patients were treated with a combination of systemic 
chemotherapy and intra-arterial Ytt-90 radioembolization for unresectable ICCs. Twenty-
seven (60%) patients had multiples lesions and/or extra-hepatic disease and were treated in a 
palliative intent. Four (9%) patients were treated for tumor recurrence. Among the 14 (31%) 
patients remaining, 4 had liver cirrhosis with portal hypertension. Eventually, 10 patients had 
single huge ICCs that developed non-cirrhotic liver without extrahepatic disease and were 
considered for potential resection. Ultimately, 8 patients (5 women and 3 men) underwent 
surgical resection with curative intent and represent our study population. The 2 remaining 
patients were not resected due to tumoral progression. (Figure 1) 
Among these eight resected patients, the initial unresectabilities were due to tumoral 
involvement of the hepatic veins (HV) of the FLR in seven cases and tumoral involvement of 
the portal pedicle of the FLR in the remaining case. The demographic data and tumor 
characteristics of the resected patients are reported in table 1. 
 
Pre-operative treatment: 
All eight patients received a median of seven cycles [range: 3 - 18] of systemic chemotherapy. 
Chemotherapy associated gemcitabine (six cases) or 5-fluorouracil (two cases) with a 
platinum salts (oxaliplatin in five cases, and cisplatin in three cases).  
Intra-arterial Ytt-90 was administered with a median injected activity of 2 GBq [1.5-3.2]. Two 
patients underwent two successive radioembolization procedures, in order to treat the entire 
tumoral volume. The median duration of chemo-radioembolization therapy (i.e., the time 
from the initiation of chemotherapy until surgery) was 7.6 months [3.4 – 16.7]. Tolerance was 
excellent, and no patient presented grade III or higher toxicity. 
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Tumor downstaging and FLRV hypertrophy: 
There was no difference between the pre- and post-treatment median TLVs (1530 ml [1200-
3580] versus 1372 ml [1255 – 2000]; p=0.16), and the tumor volume downsizing was 
significant (295 ml [90-1250] versus 168 ml [46 – 535]; p=0.02). Figures 2 show three 
representative cases of tumor shrinkage after treatment. 
There was no significant difference between the pre- and post-treatment median FLRVs (467 
ml [185 - 917] versus 507.5 ml [310 -795], respectively; p=0.46), while the median 
FLRV/TLV ratio significantly increased (27.2% vs. 35.9%, p=0.04) and was greater than 30% 
in 7 cases [30.0% – 49.7%]. The remaining patient had a pre-treatment FLRV/TLV ratio of 
23.8%, which reached 38.5 % after PVE. 
 
Surgical procedure: 
The resections were performed in situ with the exception of one patient who underwent an ex 
vivo surgery because complex vascular reconstruction was required. Extended hepatectomies 
(i.e., resection of at least five segments) were performed in all cases including right 
hepatectomies extended to segment 1 in two cases (25%), right trisectionectomy extended to 
segment 1 in five cases (62.5%) and a left trisectionectomy in one case (12.5%).19 
The biliary confluence and the extrahepatic biliary tree were resected in two cases with bilio-
enteric reconstruction. The retro-hepatic inferior vena cava (IVC) was resected in four cases 
(laterally in two cases and totally in two cases with vascular prosthetic replacement). The 
median duration of surgery was 210 min [150-600]. All in situ resections were performed 
under continuous simultaneous clamping of the portal pedicle and the infrahepatic IVC. Three 
(37.5%) patients required blood transfusion. 
R0 resection was achieved in all patients. 
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Postoperative course (table 2): 
 Three (37.5%) patients experienced Clavien-Dindo complication of grade 3 or more during 
their hospital stays. Among these three patients, two died. One patient had a sudden massive 
stroke on postoperative day 9 (1 day before planned discharge). The second patient had 
undergone an ex vivo resection of the tumor with arterial, portal and suprahepatic vein 
reconstructions and developed severe liver failure due to thrombosis of both the hepatic artery 
and portal vein. Urgent liver revascularization did not prevent the fatal evolution at 
postoperative day 4. 
None of the remaining patients exhibited bile leakage or post-operative hemorrhage.  
The median hospital stay duration was 9.5 days [4 – 21]. 
 
 Midterm evolution and survival analysis 
The median follow up time of the entire serie was 15.6 months [4 – 40.7] from the initiation 
of medical treatment and 7.2 months [0.13 - 36.4] from the date of surgery. 
Among the six patients who survived the postoperative period, one patient (aged 80 years old) 
died 6.5 months after surgery (14 months after the initiation of treatment) without evidence of 
initial disease recurrence, and five patients were still alive (figure 3). The median follow-up 
for these six patients was 16.9 [15.2 – 40.7] months after the initiation of medical treatment 
(8.2 [2 – 36.4] months after surgery). 
Two patients experienced recurrences. One patient exhibited lung metastasis 19 months after 
surgery and received chemotherapy and stereotaxic radiotherapy and is still alive 36.4 month 
after the surgery (40.7 months after medical treatment initiation). The other patient exhibited 
multiple-site metastases (lung, liver, and liver hilum lymph nodes) 7 months after surgery 
 11 
(15.1 month after the initiation of medical treatment). The median disease-free survival was 
19.1 months when considering recurrence only. 
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Discussion 
ICC is a primary liver tumor whose incidence and mortality are increasing in western 
countries.5 Complete surgical resection is the only available treatment that allows for 
prolonged survival. For unresectable patients, survival without treatment is under one year.20  
As the lesion remains clinically silent, ICCs are generally diagnosed at an advanced stage, and 
only a minority of patients can be resected. Indeed, Tan et al.7 reported a global resection rate 
of 12 %, with only 37% of the potentially resectable patients (defined by single unilobar 
tumors without evidence of vascular invasion) who were eventually resected. 
In the present study, of the 10 patients who were eligible for surgery, eight (80%) patients 
with single localized ICCs who were initially considered unresectable were offered a 
complete resection after the induction treatment of combined chemotherapy and Ytt-90 
radioembolization.    
For unresectable ICCs, systemic chemotherapy (associating Gemcitabine and platinum salt) 
produces a response rate of 20-35% and a median overall survival of 10 - 15 month. 21-25 Such 
low efficiency is also associated with a high rate of grade 3 - 4 toxicity.21 Ytt-90 
radioembolization is a novel and promising therapy for the palliative treatment of ICC, and, to 
our knowledge, five studies (two from the same team) have reported median overall survivals 
of 9.3 to 22 months after treatment.13-16, 26  In a study by Ibrahim et al., 13 one patient was 
downstaged to resection, and another patient was downstaged to liver transplantation. This 
study was expanded to 46 patients,16 and three additional patients were eventually resected or 
transplanted. Saxena et al.14 also reported one patient who was downstaged to surgery. 
Reported tolerances of Ytt-90 radioembolization were excellent and usually better than other 
intra-arterial treatment.27, 28 In our study, no patients presented severe toxicity (grade III or 
higher) and particularly no liver adverse effect. Moreover, as no postoperative bile leakage 
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was observed, we could consider that Ytt-90 radioembolization is a suitable treatment before 
liver resection, as liver parenchyma seemed not to be altered even after multiple procedures. 
Recently, Servajean et al.29 reported a case of a huge ICC with involvement of the three 
hepatic veins that was initially non-resectable. After Ytt-90 radioembolization with resin 
microspheres (SIRS-spheres®) combined with chemotherapy (eight cycles before and four 
cycles after radioembolization), the patient underwent a left hepatectomy that was enlarged to 
segment 8 with a free margin between the tumor and the right hepatic vein.    
 In our study, 8/10 patients were eventually resected. This high percentage compared to the 
published results might have been because only solitary tumors and non-cirrhotic livers were 
considered for surgery. Indeed, we did not offer extended liver resection to patients with 
cirrhotic liver even when the FLRV was greater than 30%. For such patients, liver 
transplantation might be a potential therapeutic option. Indeed, we believe that liver 
transplantation was not an appropriate option for these patients because, in our series, 
recurrence after surgery was primarily extra hepatic (i.e., lung localizations in the two 
patients), which suggests that extra hepatic microscopic disease might have been present at 
the time of surgery. 
Although pre-operative treatment induced significant tumor volume reductions, R0 resection 
could only be achieved through extended hepatectomy with the removal of at least five 
segments, and half of the patients also had complex vascular reconstructions (including IVC 
resection in 4 cases and ex-vivo surgery in 1 case). These factors might explain our 
postoperative mortality rate. However, the mortality rate should be interpreted in light of 
Wang et al.’s nomogram, 30 which predicts 3-year survival rates below < 15% among patients 
with similar huge ICCs with vascular involvements. Moreover, it should be noted that one of 
the two postoperative deaths was not related to the surgery. 
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After complete resection, ICC’s recurrence rate remained high, and recurrence typically 
occurred within the first year after surgery. 8, 31 In our series, two of the six patients who were 
alive after the postoperative course exhibited recurrence, but no deaths related to tumor 
recurrence were observed. These findings might suggest that recurrences were managed more 
efficiently after removal of the primary lesion, and a parallel could be drawn with 
management of unresectable liver metastases from colorectal cancer.32 
Recently, Ytt-90 radioembolization was also proposed as an alternative to PVE in HCC 
cirrhotic patients.17 Our results support these findings because only one patient required PVE 
prior to surgery to increase the FLRV/TLV ratio above 30%. However, in our series, the 
increase in the FLR/TLV ratio was primarily due to liver tumor shrinkage rather than 
hypertrophy of the FLRV. 
Our series is currently the largest to report on secondarily resected patients with ICC after 
downstaging with Ytt-90 radioembolization plus systemic chemotherapy but has some 
limitations. First, our downstaging rate of 80% was biased by our patient’s selection criteria 
as we only considered patients with unique tumor on non-cirrhotic liver and without extra-
hepatic disease, which represents only 10/45 (22%) patients. Second, our population included 
only eight patients, and the median follow-up time remains limited. Therefore, we cannot yet 
outline the oncological interest of the method. However, considering the time from the 
initiation of chemotherapy, nearly all patients were followed up for more than 1 year, and one 
patient remained alive 3 years after surgery. We intentionally did not compare the survival of 
the 8 resected patients with the 37 remaining patients since these 2 groups were different 
(unresected patients had generally multiple hepatic tumours and/or extrahepatic metastases).  
 
In conclusion, our experiences is the largest serie that support the notion that Ytt-90 
radioembolization plus systemic chemotherapy might be an effective therapeutic option to 
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downstage huge, unique and initially non-resectable ICCs for secondary resections. Larger 
numbers of patients and longer follow-up times are obviously required to further validate this 
perspective.  
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Figure titles and legends: 
Figure 1  
 
 
Figure 1: Flow chart of the patients with unresectable ICCs who were treated with Ytt-90 
radioembolization and resected in our institution.  
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Figure 2  
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Figure 2: Three representative cases of tumor downstaging from our series. 
 A: A 66-year-old woman with a 9-cm lesion. Initially, the tumor deeply infiltrated the right anterior 
section up to the median hepatic vein. After treatment, tumor downstaging and left liver hypertrophy 
allowed for the safe performance of a right hepatectomy that extended to segment 1 with partial 
resection of inferior retro-hepatic vena cava.    
B: A 39-year-old man with a 20-cm lesion. Initially, the tumor was in contact with the origin of the left 
portal pedicle and involved the three hepatic veins. After treatment, significant downstaging of the tumor 
and hypertrophy of the left liver allowed for the performance of a R0 right trisectionectomy with resection 
of the inferior retro-hepatic vena cava. 
C: A 70-year-old woman with a 6.5-cm-diameter central lesion. Initially, the tumor seemed to infiltrate 
the left portal pedicle. After treatment, the tumor shrinkage and liver remnant hypertrophy allowed for 
the performance of a right trisectionectomy that extended to segment 1 with biliary confluence resection.  
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Figure 3:  
A   
 
Figure 3: Overall survival of the resected patients. 
A: Overall survival from the day of surgery. 
B: Overall survival from the initiation of chemotherapy. 
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Table 1: Clinical features of the resected patients. 
 
Variables                                                                                            
 
Age (years) * 
 
68 [39 - 79] 
Sex ratio (M/F) 0.6 (3/5) 
BMI* 23 [19 - 27] 
ASA score 
           0 
           1 
           2 
 
2 (25%) 
4 (50%) 
2 (25%) 
ECOG status 
           0 
           1 
           2 
 
4 (50%) 
4 (50%) 
0 
CA 19-9 level (KU/l) at time of diagnosis*           18.5 [10 – 1125] 
Tumor size* before treatment (cm) 9.2 [6.5 – 20] 
Vascular involvement of the FLR 
         Artery 
         Portal vein 
         Hepatic veins 
         Retro hepatic inferior vena cava 
         Biliary confluence 
         Lymph node invasion  
                          hilar 
                         distant 
 
0 
1 (12.5%) 
7 (87.5%) 
4 (50%) 
2 (25%) 
3 (37.5%) 
3 (37.5%) 
2 (25%) 
Tumor distribution 
         Unilobar 
         Bilobar 
 
3 (37.5%) 
5 (62.5%) 
* median value [range]. 
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Table 2: Operative and post-operative parameters. 
Variables  
 
Major resection 
         right-side hepatectomy 
         left-side hepatectomy 
 
8 (100%) 
7 (87.5%) 
1 (12.5%) 
Number of segments resected* 6 [5 – 6] 
Duration (min)* 210 (150 -600) 
Transfusion  3 (37.5%) 
Bile leakage  
Liver failure 
Postoperative hemorrhage 
Ascitis 
Reoperation 
0 
2 (25%) 
0 
3 (37.5%) 
2 (25%) 
Clavien classification: 
              <3 
              3 
              4 
              5 
 
5 (62.5%)  
1 (12.5%) 
0  
2 (25%) 
Hospital stay duration (days)* 9.5 [4-21] 
* Median values [ranges]. 
 
 
 
